CereVasc has raised $85 Million in new Series C funding

June 23, 2026 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, CereVasc has raised $85 Million in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Piper Sandler Merchant Banking, Johnson & Johnson Innovation JJDC, Inc., Johnson & Johnson’s corporate venture capital arm, Medtronic, Bain Capital Life Sciences, and Perceptive Xontogeny Venture Funds

About CereVasc
Located in Massachusetts’ healthcare hub, CereVasc, Inc. is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components designed to treat CH without invasive surgery.

To learn more, visit https://cerevasc.com/
Linkedin: https://www.linkedin.com/company/cerevasc/

Contact:
Dan Levangie, Chief Executive Officer
https://www.linkedin.com/in/daniel-levangie-413bb751/